1
|
Hadzi-Petrushev N, Stojchevski R, Jakimovska A, Stamenkovska M, Josifovska S, Stamatoski A, Sazdova I, Sopi R, Kamkin A, Gagov H, Mladenov M, Avtanski D. GLUT5-overexpression-related tumorigenic implications. Mol Med 2024; 30:114. [PMID: 39107723 PMCID: PMC11304774 DOI: 10.1186/s10020-024-00879-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2024] [Accepted: 07/17/2024] [Indexed: 08/10/2024] Open
Abstract
Glucose transporter 5 (GLUT5) overexpression has gained increasing attention due to its profound implications for tumorigenesis. This manuscript provides a comprehensive overview of the key findings and implications associated with GLUT5 overexpression in cancer. GLUT5 has been found to be upregulated in various cancer types, leading to alterations in fructose metabolism and enhanced glycolysis, even in the presence of oxygen, a hallmark of cancer cells. This metabolic shift provides cancer cells with an alternative energy source and contributes to their uncontrolled growth and survival. Beyond its metabolic roles, recent research has unveiled additional aspects of GLUT5 in cancer biology. GLUT5 overexpression appears to play a critical role in immune evasion mechanisms, which further worsens tumor progression and complicates therapeutic interventions. This dual role of GLUT5 in both metabolic reprogramming and immune modulation highlights its significance as a potential diagnostic marker and therapeutic target. Understanding the molecular mechanisms driving GLUT5 overexpression is crucial for developing targeted therapeutic strategies that can disrupt the unique vulnerabilities of GLUT5-overexpressing cancer cells. This review emphasizes the complexities surrounding GLUT5's involvement in cancer and underscores the pressing need for continued research to unlock its potential as a diagnostic biomarker and therapeutic target, ultimately improving cancer management and patient outcomes.
Collapse
Affiliation(s)
- Nikola Hadzi-Petrushev
- Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, 1000, North Macedonia
| | - Radoslav Stojchevski
- Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, 110 E 59th Street, New York, NY, 10022, USA
- Feinstein Institutes for Medical Research, Manhasset, NY, 11030, USA
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, 11549, USA
| | - Anastasija Jakimovska
- Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, 1000, North Macedonia
| | - Mimoza Stamenkovska
- Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, 1000, North Macedonia
| | - Slavica Josifovska
- Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, 1000, North Macedonia
| | - Aleksandar Stamatoski
- Faculty of Dental Medicine, University Clinic for Maxillofacial Surgery in Skopje, Ss. Cyril and Methodius University, Skopje, 1000, North Macedonia
| | - Iliyana Sazdova
- Department of Animal and Human Physiology, Faculty of Biology, Sofia University 'St. Kliment Ohridski', Sofia, 1504, Bulgaria
| | - Ramadan Sopi
- Faculty of Medicine, University of Prishtina, Prishtina, 10 000, Kosovo
| | - Andre Kamkin
- Institute of Physiology of the Federal State Autonomous Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" Ministry of Health, Moscow, Russian Federation
| | - Hristo Gagov
- Department of Animal and Human Physiology, Faculty of Biology, Sofia University 'St. Kliment Ohridski', Sofia, 1504, Bulgaria
| | - Mitko Mladenov
- Institute of Biology, Faculty of Natural Sciences and Mathematics, Ss. Cyril and Methodius University, Skopje, 1000, North Macedonia
- Institute of Physiology of the Federal State Autonomous Educational Institution of Higher Education "N.I. Pirogov Russian National Research Medical University" Ministry of Health, Moscow, Russian Federation
| | - Dimiter Avtanski
- Friedman Diabetes Institute, Lenox Hill Hospital, Northwell Health, 110 E 59th Street, New York, NY, 10022, USA.
- Feinstein Institutes for Medical Research, Manhasset, NY, 11030, USA.
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, 11549, USA.
| |
Collapse
|
2
|
Margawati H, Yustisia I, Hardjo M, Natsir R, Azis I, Hafiyani L, Aswad H. GLUT5, GLUT7, and GLUT11 expression and Bcl-2/Bax ratio on Breast Cancer Cell Line MCF-7 Treated with Fructose and Glucose. Asian Pac J Cancer Prev 2023; 24:3917-3924. [PMID: 38019251 PMCID: PMC10772771 DOI: 10.31557/apjcp.2023.24.11.3917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2023] [Accepted: 11/12/2023] [Indexed: 11/30/2023] Open
Abstract
OBJECTIVE Fructose and glucose are types of sugars commonly found in the diet that have been linked to cancer development. Glucose transporters (GLUTs) are facilitating the uptake of these hexoses. Expression of GLUT5 is higher in cancer cells than in healthy tissue. GLUT7 and GLUT11 facilitate the transport of glucose and fructose; however, their expression in breast cancer has not been extensively studied. The Bcl-2 family has been known as a regulator of the cell's survival and death. Here, we investigated the effect of the fructose-glucose combination in MCF-7 breast cancer cells on the viability, migration, and expression of GLUT5, GLUT7, GLUT11, and Bcl-2/Bax ratio. METHODS Breast cancer cells MCF-7 were treated with fructose, glucose, and combinations of fructose:glucose (75%:25%, 50%:50%, 25%:75%). Cell viability was assessed using an MTT test. Cell migration was examined with a wound-healing assay. Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) was performed to evaluate the mRNA expression of GLUT5, GLUT7, GLUT11, and Bcl-2/Bax. RESULTS The viability and migration of MCF-7 breast cancer cells elevated when treated with a combination of fructose and glucose, and glucose alone, compared to fructose alone. The expression levels of GLUT5 and GLUT7 were highest in combination of fructose:glucose (75%:25%). Conversely, the expression of GLUT11 was consistently low across all treated media. The highest Bcl-2/Bax ratio was shown in fructose:glucose combination (25%:75%). CONCLUSION The viability, migration, and Bcl-2/Bax ratio are enhanced in the combination media with higher glucose. In contrast, when the fructose composition was higher in the media, expression of GLUT5 and GLUT7 increased.
Collapse
Affiliation(s)
- Harlindah Margawati
- Master Programme of Biomedical Sciences, Graduate School Universitas Hasanuddin, Makassar, Indonesia.
- Makassar Medical State Laboratory, Indonesian Ministry of Health, Makassar, Indonesia.
| | - Ika Yustisia
- Department of Biochemistry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.
| | - Marhaen Hardjo
- Department of Biochemistry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.
| | - Rosdiana Natsir
- Department of Biochemistry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.
| | - Ilhamuddin Azis
- Department of Biochemistry, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.
| | - Lia Hafiyani
- Department of Pharmacology, Faculty of Medicine, Universitas Hasanuddin, Makassar, Indonesia.
| | - Hijral Aswad
- Hasanuddin University Medical Research Centre (HUMRC), Makassar, Indonesia.
| |
Collapse
|